NCT02967679View on ClinicalTrials.gov

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

March 18, 2019

Study Completion Date

March 18, 2019

Conditions
Chronic Inflammatory Demyelinating PolyneuropathyPeripheral NeuropathyCharcot-Marie-Tooth DiseaseCharcot-Marie-Tooth Disease Type 1ACharcot-Marie-Tooth Disease, Type 1BAnti-MAG Neuropathy
Interventions
DRUG

MD1003

Trial Locations (1)

94010

Hôpital Henri Mondor, Créteil, France, Créteil

Sponsors
All Listed Sponsors
lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT02967679 - SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study | Biotech Hunter | Biotech Hunter